Related references
Note: Only part of the references are listed.Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Sander F. Garrelfs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up
Sander F. Garrelfs et al.
KIDNEY INTERNATIONAL (2019)
Outrageous prices of orphan drugs: a call for collaboration
Lucio Luzzatto et al.
LANCET (2018)
Vitamin B6 in Primary Hyperoxaluria I: First Prospective Trial after 40 Years of Practice
Heike Hoyer-Kuhn et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type
Giorgia Mandrile et al.
KIDNEY INTERNATIONAL (2014)
Mutations in DHDPSL Are Responsible For Primary Hyperoxaluria Type III
Ruth Belostotsky et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2010)
Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele
CG Monico et al.
KIDNEY INTERNATIONAL (2005)
Primary hyperoxaluria type 1 in the Canary Islands:: A conformational disease due to I244T mutation in the P11 L-containing alanine:glyoxylate aminotransferase
A Santana et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
